{"classes":[{"categories":[{"measurements":[{"comment":"Number of participants analyzed was less than 3, thus standard deviation was not calculated.","groupId":"OG000","spread":"NA","value":"0"},{"groupId":"OG001","spread":"0.448","value":"0.381"},{"groupId":"OG002","spread":"6.85","value":"5.32"},{"groupId":"OG003","spread":"1.52","value":"5.36"},{"groupId":"OG004","spread":"2.84","value":"6.66"},{"comment":"Number of participants analyzed was less than 3, thus standard deviation was not calculated.","groupId":"OG005","spread":"NA","value":"14.6"},{"groupId":"OG006","spread":"9.03","value":"26.0"},{"groupId":"OG007","spread":"13.5","value":"62.7"},{"groupId":"OG008","spread":"57.2","value":"159"},{"groupId":"OG009","spread":"57.3","value":"165"},{"groupId":"OG010","spread":"215","value":"238"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"9"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"CP-751,871 0.025 milligram/kilogram (mg/kg) administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG000","title":"CP-751,871 0.025 mg/kg"},{"description":"CP-751,871 0.05 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG001","title":"CP-751,871 0.05 mg/kg"},{"description":"CP-751,871 0.1 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG002","title":"CP-751,871 0.1 mg/kg"},{"description":"CP-751,871 0.2 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG003","title":"CP-751,871 0.2 mg/kg"},{"description":"CP-751,871 0.4 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG004","title":"CP-751,871 0.4 mg/kg"},{"description":"CP-751,871 0.8 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG005","title":"CP-751,871 0.8 mg/kg"},{"description":"CP-751,871 1.5 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG006","title":"CP-751,871 1.5 mg/kg"},{"description":"CP-751,871 3 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent Cycles, starting from Cycle 2 (4 weeks)","id":"OG007","title":"CP-751,871 3 mg/kg"},{"description":"CP-751,871 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG008","title":"CP-751,871 6 mg/kg"},{"description":"CP-751,871 10 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG009","title":"CP-751,871 10 mg/kg"},{"description":"CP-751,871 20 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG010","title":"CP-751,871 20 mg/kg"}],"paramType":"MEAN","populationDescription":"All participants treated who had at least 1 concentration.","reportingStatus":"POSTED","timeFrame":"1 hour postdose in Cycle 1","title":"Single Dose End-of-infusion Concentration (Cinf) for CP-751,871","type":"SECONDARY","unitOfMeasure":"milligram/liter (mg/L)"}